Bayer seeks Japanese marketing approval for finerenone to treat adult patients with chronic heart failure: Berlin Saturday, February 15, 2025, 14:00 Hrs [IST] Bayer announced the ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

Slower gait speed, but not handgrip strength or muscle mass, is associated with an increased risk for cardiovascular outcomes ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

Peripartum cardiac insufficiency (PPCM) is a rare but life-threatening condition that can affect previously heart-healthy women a few weeks before or after the birth of a child. For unknown reasons, ...

A national clinical trial is underway to compare a novel mechanical heart pump to the only device currently used to treat end-stage heart failure. The INNOVATE study, led by University of Michigan, wi ...

A multi-institutional research team led by Osaka University found that tricaprin, a natural supplement, improved long-term ...

The ancient Greek philosopher and polymath Aristotle once concluded that the human heart is tri-chambered and that it was the ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

The FDA today issued a notice informing customers of updated instructions for the Johnson & Johnson Abiomed Impella RP heart ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...